An earlier study demonstrated that miR-483 targets metalloproteinase 2 (TIMP2) and platelet-derived growth factor-β (PDGF-β), thus suppressing CCl4-mediated mouse liver fibrosis in vivo [35]. This evidence concerns the gene TIMP2 and Hepatic fibrosis.